Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Moleculin Biotech CS (MBRX)

Moleculin Biotech CS (MBRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 46,101
  • Shares Outstanding, K 45,197
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,880 K
  • 60-Month Beta 1.90
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.12
  • Number of Estimates 2
  • High Estimate -0.10
  • Low Estimate -0.13
  • Prior Year -0.10
  • Growth Rate Est. (year over year) -20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.01 +0.99%
on 12/06/19
1.12 -8.93%
on 11/12/19
-0.04 (-3.77%)
since 11/06/19
3-Month
1.01 +0.99%
on 12/06/19
1.29 -20.93%
on 09/18/19
-0.10 (-8.93%)
since 09/06/19
52-Week
0.78 +31.24%
on 04/01/19
3.15 -67.62%
on 04/22/19
-0.25 (-19.69%)
since 12/06/18

Most Recent Stories

More News
Biotechs Move Forward Developing Latest Targeted Therapies for Acute Myeloid Leukemia

So it is not surprising that there is a lot of money and research resources being devoted to find new therapies for Acute Myeloid Leukemia (AML), many of which are in the targeted drugs arena. AML is the...

MBRX : 1.02 (unch)
BOLD : 59.25 (+0.07%)
OTLK : 1.11 (-9.76%)
AXSM : 45.43 (+5.06%)
QURE : 66.05 (+2.28%)
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 1.02 (unch)
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced it...

MBRX : 1.02 (unch)
Today's New Way to Fight Cancer Focusing on Metabolic Therapies

For decades researchers have been trying to find newer and more effective ways to fight cancer cells. Today much research is focused on attacking the cancerous cells growth. The reasoning is that denying...

MBRX : 1.02 (unch)
AMRN : 22.45 (+2.93%)
KDMN : 4.50 (+10.02%)
PFE : 38.29 (+0.68%)
ACST : 1.86 (-2.11%)
ACST.VN : 2.440 (-2.40%)
Moleculin Announces Beginning of Preclinical Development of New Approach to Pancreatic Cancer

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced it...

MBRX : 1.02 (unch)
Biotechs Seek Advancements in the Immuno-Oncology Field for Childhood Brain Tumors

Doctors are working to learn more about brain tumors, ways to prevent them, how to best treat them, and how to provide the best care to people diagnosed with a brain tumor. According to recent articles...

MBRX : 1.02 (unch)
ABBV : 86.98 (+0.30%)
NKTR : 20.45 (+2.97%)
INMD : 47.42 (+8.84%)
AGEN : 3.91 (-3.93%)
Moleculin Announces FDA Approval of IND for its STAT3 Inhibitor in Emory University Clinical Trial

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced that...

MBRX : 1.02 (unch)
Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2019

Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced...

MBRX : 1.02 (unch)
Clinical Trials in Gene Sequencing Reveal Novel Mutations Aiding in New Treatments for Acute Myeloid Leukemia

Palm Beach, FL -October 29, 2019 - Acute myeloid leukemia (AML), is the most common of the four major types of leukemia. Without treatment, AML is often deadly within a few months. Many of the symptoms...

MBRX : 1.02 (unch)
DCPH : 52.80 (+2.76%)
RIGL : 2.17 (+6.37%)
NKTR : 20.45 (+2.97%)
BDSI : 6.43 (-0.92%)
Moleculin Announces New Data Confirms Anti-tumor Efficacy of Annamycin in Both Human and Murine AML Models

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced the...

MBRX : 1.02 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade MBRX with:

Business Summary

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company which focused on the development of anti-cancer drug candidates. The company's lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia....

See More

Key Turning Points

2nd Resistance Point 1.05
1st Resistance Point 1.04
Last Price 1.02
1st Support Level 1.01
2nd Support Level 0.99

See More

52-Week High 3.15
Fibonacci 61.8% 2.24
Fibonacci 50% 1.96
Fibonacci 38.2% 1.68
Last Price 1.02
52-Week Low 0.78

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar